In June 2026, EU food safety regulators approved the sale of a GLP-1-inducing food additive, a change that may lead to 'supercharged' cereals and breads in Europe within a year. (Free w/email).

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for).

Semaglutides, which belong to a class of drugs called GLP-1s, are prescribed for weight loss in combination with diet and exercise because they trigger the release of the appetite-suppressing hormone incretin.

GLP-1s are linked to reduced worker illness and cost savings—a 2026 economic analysis finds the weight-loss drugs are tied to a 17% drop in worker sick leave days.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

GLP-1 drugs mimic a natural hormone that triggers appetite-suppressing effects

Ozempic, one of the brand names for the drug semaglutide, was originally developed in 2012, to help treat Type 2 diabetes. Among other effects, the drug mimics a naturally produced hormone known as GLP-1, which is released while eating to let our bodies know we are full.

GLP-1s may lower inflammation, possibly helping to combat cognitive decline

An analysis of existing GLP-1 research, published in April 2025, indicated that GLP-1 drugs reduce inflammation, with numerous health benefits. The work notes that GLP-1s were linked with a statistically significant reduction in dementia in randomized clinical trials.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

When people stopped using GLP-1, they regained two-thirds of the weight back.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

Insurance coverage for GLP-1s remains uneven, but Medicare began covering it in some instances in July 2026.

Saccharin was banned in Canada in the 1970s, but regulators may allow its use once again

The product, commonly known as Sweet'N Low, was banned in Canada in the late 1970s due to research indicating that the sweetener could cause cancer in lab rats. Subsequent studies have found that the rodent findings didn't hold true for humans, and so Canadian regulators state that they are considering updating their stance to allow the product to be added to certain foods (the product is currently allowed in the US).

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva.

Medicare in early 2026 did not pay for GLP-1 for obesity treatment, and coverage under Medicaid varied widely by state.

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

GLP-1s may weaken the effectiveness of birth control and affect other medications, hindering how and when they circulate through the blood.

The US FDA issued a 2025 warning about BPC-157 and other popular peptides that are marketed for various regenerative properties.

Semaglutide treatment extended the lifespan of female mice by about 12% in research published in 2026.

Hormone and peptide compounds imported from China soared in 2025

US customs data indicates that these imports doubled to $328M in the first three quarters of 2025, from $164M in the same period of 2024. The imports include GLPs, among other products. (Some users may experience a paywall.)

Sesame seed regulations have led to fewer sesame-free products

Food producers have been required to include specific labeling on their packages for sesame since new regulations went into effect in January 2023. In response, some food producers have decided to add small amounts of sesame to foods, including breads, rather than do the costly work of scrubbing their facilities of all possible sesame contamination.

Ultra-processed foods are made to maximize cravings and encourage overeating

Often disguised as healthy options like granola bars and low-fat yogurt, these foods silently fuel chronic diseases, despite dominating diets. Reviewing labels for ingredients like stabilizers and emulsifiers can serve as indicators to help identify these products.

A collection of molecular gastronomy techniques, from flavored air to turning oils into powder

Soy lecithin can be blended with flavored mixtures, such as herbs and Parmesan, to produce edible bubbles, which can be frozen into a solid foam. Maltodextrin can be combined with liquid fats in a food processor to create light, flavorful powders.

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

Fake sugars may disrupt metabolic health.

Rising fracking rates have increased prices of some food products

Every fracking well uses approximately 20,000 pounds of guar gum, a thickening and stabilizing agent commonly used in ice cream, salad dressing, and baked goods. The polysaccharide is also a key component in some cosmetics and explosives.

The dietary market is worth more than $60B

Listen to this question and answer session with the US Food and Drug Administration about dietary supplements—vitamins, minerals, probiotics and similar products people may buy in liquid, pill, or powder form. They are categorized legally as a category of food and can be legally brought to market without the FDA even knowing about it, though consumers can tell FDA about issues with the products and FDA can take action to remove dangerous or unlawful items after they're available.

Learn the history of food science breakthroughs from the 20th century

Long after humans developed the means to produce sufficient food to feed civilizations, scientific research focused on a wide variety of objectives, such as developing methods to preserve food quality (accomplished via frozen food), speeding up cooking (leading to the microwave), and lowering the cost of sweetening food, which high fructose corn syrup provides.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

Microplastics are entering human food chains through carrots, wheat, and other foodstuffs grown in farmlands fertilized by sewage sludge.

Tirzepatide: A GLP-1 drug that also acts on separate receptors to promote weight loss

Tirzepatide, like semaglutide, is a GLP-1 drug used in diabetes treatment and for weight loss. Unlike semaglutide, it also acts on glucose-dependent insulinotropic polypeptide receptors, proving a second route to reducing appetite as a means to treat diabetes and promote weight loss.

Aspartame was a surprise discovery from a lab working on gastric ulcers

As with saccharin and cyclamate, the aspartame discovery arose from its discoverer tasting something sweet from his workplace. In 1965, American chemist James Schlatter licked a white powder off his finger as he picked up a piece of paper and was startled to discover it tasted sweet. He applied for a patent for the substance, and received it in 1970. It is now one of the most popular artificial sweeteners. (Some users may experience a paywall.)

Artificial sweeteners may disrupt gut health, throwing off the balance of beneficial bacteria in the gut and shifting the composition of the microbiome.

Meet six commercially available synbio products

An article exploring the science behind synbio products currently on the market, and projecting the products that can be expected over the next 10 years.

The US FDA recently tried to regulate the expanded prenatal genetic tests

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.

In 2026, the FDA proposed a novel approach to expedite reviews of gene therapies for patients with rare genetic disorders such as cystic fibrosis, potentially bypassing the need for years-long clinical trials if approved.

The term 'superfood' is a marketing construct with no scientific or medical definition

Encompassing at least 136 plants and animals, the concept has been criticized by nutritionists for its scientific value, which has been exploited by the wellness industry for profit. Although the label has encouraged the consumption of fruits and vegetables, food variety and minimal processing remain key to a healthy diet.

CRISPR technology is removing allergens from common foods

Proteins responsible for allergies to eggs, milk, wheat, peanuts, and other foods can be genetically edited out of foods to reduce the risk of life-threatening reactions. The technique has also been used to produce caffeine-free coffee beans, spicier tomatoes, allergen-free pets, and more nutritious fish.

Scientists have created a cell from scratch—called a SpudCell—proof-of-concept work that a lab-made cell can feed, grow, and replicate like a natural cell.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.